Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Rixa Health vs Spry

Rixa Health
Graded #320

Higher grade

vs+3.700000000000003
Spry
Graded #408

Lower grade

The verdict

Rixa Health takes it — 60.5/100 to 56.8/100.

Rixa Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Rixa Health is a direct-to-consumer functional-medicine telehealth practice prescribing compounded and oral semaglutide and tirzepatide (plus other peptides) for weight loss via partner US pharmacies.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueSpry +9
45
54
Dose & formulationSpry +13
51
64
Clinical oversightRixa Health +30
85
55
Labs & monitoringRixa Health +11
63
52
FulfillmentRixa Health +17
78
61
Contract termsSpry +14
41
55
Rixa Health · left barSpry · right bar

The numbers

MetricRixa HealthSpry
WeighScore60.5/10056.8/100
GradeCC
Scorecard rank#320#408
SemaglutideNot disclosed$199/mo (starting dose, compounded)
TirzepatideNot disclosed$299/mo (starting dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Rixa Health

Graded #320 · C

Strengths

  • Functional-medicine, root-cause clinical approach
  • Compounded and oral semaglutide plus tirzepatide offered
  • Board-certified DO and FNP providers with years of experience
  • Medication bundled with visits into a single price
  • No charge until after approval

Where it loses points

  • No public monthly pricing; quoted only during consultation
  • Relies on compounded GLP-1, which is not FDA-approved as a finished drug
  • A handful of states still listed as coming soon
  • Branded GLP-1 medications are not the primary offering
  • Requires ongoing monthly follow-up commitment
Spry

Graded #408 · C

Strengths

  • Three named co-founders disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency
  • Pricing shown on the homepage ($199 semaglutide / $299 tirzepatide / $249–$299 peptides) — no full sign-up wall
  • Broader range (2 GLP-1s plus 3 anti-aging peptides) appeals to longevity buyers
  • No contracts or commitment required
  • LegitScript Certified with a public verification link

Where it loses points

  • Displays an "FDA Approved" badge though compounded GLP-1s are not FDA-approved finished drugs — potentially misleading
  • Intake reviewed by a nurse practitioner, not an MD
  • States served not disclosed publicly
  • Pharmacy partner not named, and 503A vs 503B designation not specified
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard